66. The antibody of claim 1, wherein the mature heavy chain variable region has the amino acid sequence designated SEQ ID NO:23 and the mature light chain variable region has the amino acid sequence designated SEQ ID NO: 45, 33, 35, 37, or 39.

67. The antibody of claim 22, wherein the mature heavy chain variable region has the amino acid sequence designated SEQ ID NO:25 and the mature light chain variable region has the amino acid sequence designated SEQ ID NO: 45, 33, 35, 37, or 39.

68. The antibody of claim 22, wherein the mature heavy chain variable region has the amino acid sequence designated SEQ ID NO:27 and the mature light chain variable region has the amino acid sequence designated SEQ ID NO: 45, 33, 35, 37, or 39.

69. The antibody of claim 62, wherein the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain constant region is fused to a light chain constant region.

70. The antibody of claim 69, wherein the heavy chain constant region has the amino acid sequence designated SEQ ID NO:52 provided the C-terminal lysine residue may be omitted.

71. The antibody of claim 69, wherein the light chain constant region has the amino acid sequence designated SEQ ID NO:49.

72. The antibody of claim 62, wherein the mature heavy chain variable region is fused to a heavy chain constant region having the amino acid sequence designated SEQ ID NO:52 provided the C-terminal lysine residue may be omitted and the mature light chain constant region is fused to a light chain constant region having the amino acid sequence designated SEQ ID NO:49.

73. The antibody of claim 72, wherein the mature light chain comprises SEQ ID NO:53 and the mature heavy chain comprises SEQ ID NO:56.

74. The antibody of any of claim 1, 22, 46 or 52, wherein the antibody comprises a heavy chain constant region which is a mutant form of a natural human constant region which has reduced binding to an Fc.gamma. receptor relative to the natural human constant region.

75. The antibody of any of claim 1, 22, 46 or 52, wherein the antibody comprises a heavy chain constant region of human IgG1 isotype.

76. A pharmaceutical composition comprising an antibody as defined by claim 1.

~~77. A method of detecting Lewy bodies in a patient having or at risk of a Lewy body disease, comprising administering to the patient an effective amount of an antibody as defined by claim 1, wherein the antibody binds to Lewy bodies; and detecting bound antibody in the~~

~~patient.~~

~~78~~77. The antibody of any of claim 1, 22, 46, or 52, wherein the antibody specifically binds to an epitope within amino acid residues 91-99 of human alpha synuclein.